eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2020
vol. 37
 
Share:
Share:
more
 
 
abstract:
Review paper

Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications

Elżbieta Halina Kłujszo
1
,
Piotr Parcheta
1
,
Anna B. Witkowska
2
,
Beata Kręcisz
3

1.
Department of Dermatology, Regional Hospital, Kielce, Poland
2.
Graduate of Medical University, Szeged, Hungary
3.
Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland
Adv Dermatol Allergol 2020; XXXVII (4): 468-474
Online publish date: 2019/07/25
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in the West. Psoriatic patients are at higher risk of having NAFLD, and at higher risk of experiencing the more severe form of the disease, with poorer outcomes. The components of the metabolic syndrome – obesity, lipid abnormalities, hypertension, and type 2 diabetes – significantly correlate with NAFLD progression. The inflammatory state present in psoriasis plays a significant role in development of NAFLD and the metabolic syndrome. All patients with psoriasis and insulin resistance and risk factors for metabolic syndrome should also been screened for NAFLD, and planning of the treatment options should always take into consideration the possible risks for the liver, especially in patients with NAFLD.
keywords:

psoriasis, liver disease, methotrexate, biologic agents

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe